Jeena Sikho Lifecare Limited – Investor Presentation Summary

Key Operational Highlights

  • Operational hospitals: 61
  • Cities & towns covered: 100+
  • Operational clinics & day care centres: 445
  • States covered: 23
  • Total bed capacity: 2,861 beds (2,300 beds currently operational)
  • Beds in pipeline: 58
  • SKUs in Ayurveda medicine & product portfolio: 330+
  • 3Y Top line CAGR (FY23-26): 58%
  • 3Y Average ROCE: 46%
  • IPD volumes grew by 65% to 40,454 in FY26
  • OPD volumes grew 69% to ~5.7 lakh patients in FY26
  • Certified ayurveda doctors: 592
  • Supporting health care personnel: 779
  • Franchisee operated health care centres: 33
  • NABH Accredited Hospitals & Clinics: 50 (with 3 additional in pipeline)

Key drivers of operational performance: Strong patient inflows across both IPD and OPD formats, product diversification initiatives, expanding customer reach, and continued focus on quality-led offerings.

Segment-wise Performance

  • Ayurveda Healthcare Services: Revenue growth of 52% in FY26
  • Ayurveda Healthcare Products: Growth of 93% in Q4FY26
  • Revenue contribution: Services (48%), Products (52%) in FY26

Explanation of significant changes in segment performance: Growth in both segments driven by increasing awareness and acceptance of Ayurvedic healthcare solutions across India, product diversification, and expanding customer reach.

Financial Highlights

  • Revenue: ₹801 Cr (FY26)
  • Gross Profit: ₹70,986 lakhs (FY26)
  • Gross Profit Margin: 89% (FY26)
  • Operating Expenses: ₹36,023 lakhs (FY26)
  • EBITDA: ₹34,963 lakhs (FY26)
  • EBITDA Margin: 44% (FY26)
  • PAT: ₹22,218 lakhs (FY26)
  • PAT Margin: 27% (FY26)
  • EPS: ₹17.87 (FY26)

YoY/QoQ comparison: Q4FY26 PAT decreased 32% to ₹4,535 lakhs from ₹6,673 lakhs in Q3FY26, but increased 79% from ₹2,534 lakhs in Q4FY25. FY26 PAT increased 178% from ₹7,994 lakhs in FY25.

Drivers of financial performance: Operating leverage, improved asset utilization, increasing scalability across both business verticals, and strong volume growth.

Key Risks: Reported margins were affected by one-off employee-related provisions (~₹7 Cr), a one time ECL provision (~₹5 Cr), and Ind AS transition-related adjustments (~₹9 Cr) in Q4FY26.

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Balance Sheet Snapshot

  • Total Equity: ₹46,740 lakhs (FY26)
  • Non-Current Liabilities: ₹10,231 lakhs (FY26)
  • Current Liabilities: ₹10,341 lakhs (FY26)
  • Total Assets: ₹67,312 lakhs (FY26)
  • Property, Plant and Equipment: ₹11,701 lakhs (FY26)
  • Inventories: ₹2,017 lakhs (FY26)
  • Trade Receivables: ₹6,993 lakhs (FY26)
  • Cash and Cash Equivalents: ₹1,516 lakhs (FY26)

Financial Health Insights: Debt-free business model with superior ROCE of 46% (3Y average).

Capex & Cash Flow Health

  • Cash from Operating Activities: ₹26,199.25 lakhs (FY26)
  • Cash from Investing Activities: ₹(21,108.76) lakhs (FY26)
  • Cash from Financing Activities: ₹(5,872.74) lakhs (FY26)
  • Net Cash Flow: ₹(782.25) lakhs (FY26)
  • Capital Expenditure: Setup cost of ₹3-4 lakh per bed for typical 100-bed facility

Investment Rationale: Focus on capacity expansion with capital-light model requiring ₹250-350 lakhs for smaller hospitals.

Strategic & R&D Initiatives

  • Launched Jeena Sikho Health Card for patient loyalty through referral benefits and diagnostic discounts
  • Product pipeline includes Plant Based Protein Powder, Gyno Syrup, Joint Pain products (Oil, Ointment, Balm, Tablets)
  • All products compliant with AYUSH Standards
  • Research includes Nobel Prize-recognized Seed & Soil Theory and multiple other validated scientific frameworks

Expected impact on growth: Health card program in trial phase with encouraging early response; new products to expand portfolio.

Strategic Rationale: Expanding into high-growth markets through hub-and-spoke model, reducing operational costs through franchise partnerships.

Industry Trends & Business Environment

Macro/Industry Trends: Large, unserved need for alternate medicine in India with estimated ~1.9 million hospital beds.

Impact on Company: Continued rise in awareness and acceptance of Ayurvedic healthcare solutions across India strengthening demand visibility.

Management Commentary & Growth Outlook

Strategic Outlook: "With the strong foundation we have built over the years, we are now better positioned than ever to deliver on that commitment."

FY Guidance: Not Specified

Market Share Targets: Positioned as leading organised player in Ayurveda healthcare chain.

Risks and Opportunities: Board recommended final dividend of ₹4.50 per equity share for FY2025-26, subject to shareholder approval.

Additional Headings

Insurance & Government Panel
  • Empanelled for government employees of Uttar Pradesh, Bihar, Haryana and Punjab
  • Empanelled with CGHS, CAPF and ECHS
  • Additional empanelments with DDA, CBSE, CSIR, DERC, DHC, BIS, and multiple other government and private organizations
Marketing & Outreach
  • Social media presence across multiple platforms with millions of followers
  • 431 health care camps organized in Q4FY26
  • Cumulative OPD, COD & Consultation customers: 14.10 lakhs
  • Presence on National & Regional TV, Radio, News Papers and Cinema